Muhammad Suleman

57196800921

Publications - 3

Exploring the hub gene CERS6 as a therapeutic target in type 1 diabetes through a bioinformatics and network analyst approach

Salman Alrokayan Khalid Muhammad D. U. Ozsahin Y. Waheed Muhammad Suleman Hassan Ayaz Tajamul Hussain Muhammad Suleman Asia Nawaz D. U. Ozsahin

Publication Name: Scientific Reports

Publication Date: 2026-12-01

Volume: 16

Issue: 1

Page Range: Unknown

Description:

Insulin-producing β-cells are destroyed in type 1 diabetes mellitus (T1DM), a chronic autoimmune disease that results in complete insulin insufficiency and metabolic dysfunction. According to a survival study that used p values, some hub genes are important for predicting and diagnosing illness. Scientists have inferred medicines to identify possible therapies that interact with the identified hub genes. The GSE10586 gene expression dataset from the Gene Expression Omnibus (GEO) was used for this investigation, which included 27 samples from 15 healthy controls and 12 diabetic patients. Normalization methods such as variance stabilization normalization (VSN) were used as part of the data pretreatment. A protein‒protein interaction (PPI) network was constructed, principal component analysis (PCA) was performed, heatmaps were created, and the Limma algorithm was used to analyze differential gene expression. Using DAVID v6.8 and KEGG pathway annotations, the functional enrichment of differentially expressed genes (DEGs) was evaluated. Furthermore, a computational study revealed CERS6 to be one of the potential hub genes. Four drugs, methotrexate, eliglustat, myriocin and statin, were the focus of further studies on the basis of predictions made via ChemSpider and PubChem database analysis. To determine the optimal binding positions of these drugs with CERS6, we used molecular docking techniques. The binding affinity of methotrexate was 8.48 kcal/mol, that of myriocin was 7.85 kcal/mol, that of eliglustat was − 6.62 kcal/mol, and that of serine was − 4.90 kcal/mol against the binding pocket’s active residues. To determine how consistently each drug interacted with the CERS6 protein over time, molecular dynamics (MD) simulations were run. Throughout the simulation intervals, both medications were confirmed to be stable, with minor alterations in the CERS6 protein loop region. Therefore, the investigation of structure-based drug design has potential for identifying specific therapeutic targets. Ten hub genes were identified via network analysis of differentially expressed genes. These hub genes could serve as novel targets for T1DM detection, prognosis, and targeting. CERS6 exhibited the highest degree of interaction. Methotrexate, eliglustat, myriocin and statins were identified as potential drugs for CERS6. Overall, these findings provide valuable insights that could pave the way for new experimental strategies in T1DM therapy.

Open Access: Yes

DOI: 10.1038/s41598-025-30045-x

Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study

Muhammad Suleman Masood Ali Shaikh Jiseung Kang Sa’ed H. Zyoud Chuanhua Yu Naohiro Yonemoto Manish Vinayak Georgios Ioannis Verras Siavash Vaziri Hyeon Jin Kim Min Seo Kim Magdalena Zielińska Bin Zhu Paul Yip Dehui Yin Renjulal Yesodharan Tommi Juhani Vasankari Joe Varghese Jef Van den Eynde Munkhtuya Tumurkhuu Abdul Rohim Tualeka Evangelia Eirini Tsermpini Alexander C. Tsai Samuel Joseph Tromans Aristidis Tsatsakis Atta Ullah Masayuki Teramoto Mohamad Hani Temsah Reem Temsah Yonas Getaye Tefera Vinay Suresh Vetriselvan Subramaniyan Dan J. Stein Chandrashekhar T. Sreeramareddy Joan B. Soriano Roman Shrestha Sunil Shrestha Pavanchand H. Shetty Premalatha K. ShettyS Minale Tareke Seyed Afshin Shorofi Soroush Soraneh Amin Sharifan Ujjawal Sharma Manoj Sharma Javad Sharifi Rad Alfiya Shamsutdinova Ireneous N. Soyiri Aminu Shittu Sunder Sham Anthony Zhong Jingya Zhang Haijun Zhang Mohammed G.M. Zeariya Aurora Zanghì Marcos Roberto Tovani-Palone Jovana Todorovic Marco Torrado Tenaw Yimer Tiruye Kavumpurathu Raman Thankappan Baljinder Singh Jasvinder A. Singh Luís Manuel Lopes Rodrigues Silva João Pedro Silva Inga Dora Sigfusdottir Emmanuel Edwar Siddig Mahabalesh Shetty Ali Sheidaei Vishal Sharma Angga Wilandika Nuwan Darshana Wickramasinghe Yuan Pang Wang Mandaras Tariku Walde Isidora S. Vujcic Shu Wang Asokan Govindaraj Vaithinathan Saeed Ullah Nguyen Tran Minh Duc Thang Huu Tran Mircea Tampa Seyyed Mohammad Tabatabaei Rafael Tabarés-Seisdedos Lukasz Szarpak Chandan Kumar Swain Payam Tabaee Damavandi Alireza Shakeri Masood Ali Shaikh Aniefiok John Udoakang Matiwos Soboka Mehran Shams-Beyranvand Y. Waheed Farrukh Sobia Anna Aleksandrovna Skryabina Valentin Yurievich Skryabin Surjit Singh Fathiah Zakham Hadiza Yusuf Zwanden Sule Yahaya Harmanjit Singh Sa’ed H. Zyoud Asokan Govindaraj Vaithinathan Paramdeep Singh Shu Wang Ker Kan Tan Pavanchand H. Shetty Premalatha K. ShettyS Marco Torrado

Publication Name: Nature Medicine

Publication Date: 2026-02-01

Volume: 32

Issue: 2

Page Range: 527-544

Description:

Drug use disorders (DUDs) are emerging global public health challenges. Here we investigated the global and regional estimates of the prevalence and burden of DUDs, including amphetamine, cannabis, cocaine and opioid use disorders, from 1990 to 2023 for 204 countries and territories by using the Global Burden of Disease Study 2023. Overall, trends in global age-standardized disability-adjusted life-years of DUDs increased from 169.3 (95% uncertainty interval (95% UI), 134.4–203.9) per 100,000 people in 1990 to 212.0 (95% UI, 179.2–245.6) in 2023. In 2023, both prevalence and burden of DUDs were higher in high-income countries, particularly in the USA. The most prevalent DUDs in 2023 were cannabis use disorder (age-standardized prevalence, 270.8 (95% UI, 201.7–350.0) per 100,000 people) and opioid use disorder (205.9 (95% UI, 178.7–235.0)). Particularly, opioid use disorder showed a nearly twofold increase in prevalence and burden between 1990 and 2023. In 2023, compared with countries where cannabis use was illegal, countries permitting both recreational and medical cannabis use had higher prevalence rates for all types of DUDs. Proactive and effective policies are essential to mitigate the increasing global burden of DUDs.

Open Access: Yes

DOI: 10.1038/s41591-025-04137-0

Author Correction: Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study (Nature Medicine, (2026), 32, 2, (527-544), 10.1038/s41591-025-04137-0)

Luís Manuel Lopes Rodrigues Silva Ireneous N. Soyiri Aminu Shittu Ker Kan Tan Siavash Vaziri Farrukh Sobia Seyed Afshin Shorofi Y. Waheed Alexander C. Tsai Abdul Rohim Tualeka Fathiah Zakham Lukasz Szarpak Ujjawal Sharma Mircea Tampa Nuwan Darshana Wickramasinghe Manoj Sharma Marco Torrado Surjit Singh Baljinder Singh Emmanuel Edwar Siddig Dehui Yin Seyyed Mohammad Tabatabaei Isidora S. Vujcic Evangelia Eirini Tsermpini Yonas Getaye Tefera Ali Sheidaei Mohamad Hani Temsah Sunil Shrestha Matiwos Soboka Marcos Roberto Tovani-Palone Vetriselvan Subramaniyan Samuel Joseph Tromans Aurora Zanghì Hadiza Yusuf Minale Tareke Mehran Shams-Beyranvand Tenaw Yimer Tiruye Inga Dora Sigfusdottir Bin Zhu Zwanden Sule Yahaya Muhammad Suleman Nguyen Tran Minh Duc Tommi Juhani Vasankari Renjulal Yesodharan Paramdeep Singh Kavumpurathu Raman Thankappan Masood Ali Shaikh Min Seo Kim João Pedro Silva Naohiro Yonemoto Chuanhua Yu Chandrashekhar T. Sreeramareddy Harmanjit Singh Atta Ullah Jiseung Kang Shu Wang Haijun Zhang Aniefiok John Udoakang Saeed Ullah Alireza Shakeri Anna Aleksandrovna Skryabina Reem Temsah Masayuki Teramoto Amin Sharifan Georgios Ioannis Verras Valentin Yurievich Skryabin Mohammed G.M. Zeariya Joe Varghese Soroush Soraneh Angga Wilandika Mandaras Tariku Walde Anthony Zhong Jef Van den Eynde Vishal Sharma Sunder Sham Hyeon Jin Kim Vinay Suresh Thang Huu Tran Manish Vinayak Jingya Zhang Magdalena Zielińska Asokan Govindaraj Vaithinathan Paul Yip Chandan Kumar Swain Munkhtuya Tumurkhuu Dan J. Stein Javad Sharifi Rad Sa’ed H. Zyoud Roman Shrestha Pavanchand H. Shetty Payam Tabaee Damavandi Premalatha K. ShettyS Aristidis Tsatsakis Alfiya Shamsutdinova Rafael Tabarés-Seisdedos Jovana Todorovic Mahabalesh Shetty Joan B. Soriano Jasvinder A. Singh Yuan Pang Wang

Publication Name: Nature Medicine

Publication Date: 2026-01-01

Volume: Unknown

Issue: Unknown

Page Range: Unknown

Description:

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-025-04137-0, published online 16 January 2026. In the original version of this article, errors and omissions were identified in the Competing Interests statements of several authors among the GBD 2023 Substance Use Collaborators. Following a comprehensive review of all competing interest declarations, corrections were required for nine authors. The competing interests statement for S. Afzal was incomplete. The statement has been amended to include grants or contracts from the Dean Office, Institute of Public Health Lahore. The competing interests statement for L. Monasta was incomplete. The statement has been amended to include support for the present manuscript from the Italian Ministry of Health to the Institute for Maternal and Child Health – IRCCS Burlo Garofolo, with payments made to the institution under project RC 34/2027; all outside the submitted work. The competing interests statement for J.P.S. was incomplete. The statement has been amended to include support for the present manuscript from the Portuguese Foundation for Science and Technology, including payment of salary under contract reference 2021.01789.CEECIND/CP1662/CT0014; all outside the submitted work. The competing interests statement for L.M.L.R.S. contained inaccuracies regarding the sources of grants or contracts. The statement has been corrected to accurately reflect support received from SPRINT – Sport Physical Activity and Health Research & Innovation Center, Polytechnic of Guarda, 6300-559 Guarda, Portugal and RISE–Health, Faculty of Health Sciences, University of Beira Interior, 6201-506 Covilhã, Portugal. The competing interests statement for J.A.S. was incomplete. The statement has been amended to include stock or stock options in Atyr Pharmaceuticals. The competing interests statement for A.C.T. contained an incorrect NIH grant number. The grant number has been corrected from K34DA061696 to K24DA061696. The competing interests statements for B. Oancea, K. Krishan, and I. N. Soyiri were omitted from the version of this article initially published. The statements have now been added and read as follows: “B.O. reports grants from the Core Program within the Romanian National Research, Development, and Innovation Plan 2022–2027, carried out with the support of MRID, project no. 23020101 (SIA-PRO), contract no. 7N/2022, and project PNRR-I8 no. 842027778, contract no. 760096. K. Krishan reports non-financial support from the UGC Centre of Advanced Study (CAS II), awarded to the Department of Anthropology, and support from the RUSA 2.0 grant awarded by the Ministry of Education to Panjab University, Chandigarh, India; all outside the submitted work. I.N.S. reports a leadership or fiduciary role in another board, society, committee, or advocacy group, paid or unpaid, as a trustee of the Citizens Advice Bureau for Hull & East Riding, United Kingdom.” These errors have now been corrected in the HTML and PDF versions of the article. No other parts of the article have been changed.

Open Access: Yes

DOI: 10.1038/s41591-026-04513-4